IGF-LR3Understand the science
How laboratories distinguished intact LR3 from breakdown products
2 numbered sourcesSource years 1992, 2021
Short chains of amino acids linked by peptide bonds can change when an enzyme cuts the chain or a chemical reaction alters a residue. IGF-LR3 is an engineered 83-amino-acid version of insulin-like growth factor 1. It includes a 13-residue extension at the beginning and an arginine substitution in the original sequence. How did researchers distinguish the intact molecule from closely related compounds in blood samples? [1, 2]
No recent primary study replacing this exact analytical comparison was identified. In the older 2021 work, researchers developed a method that used an antibody to help isolate IGF-related molecules before separating them and measuring their mass with a sensitive instrument. They tested the method using human serum to which the researchers added known amounts of several IGF-1 analogues. The method allowed them to distinguish Long R3 from the shorter des(1–3) variant and other related molecules. [1]
The team separately looked at samples from rats that had received the research compounds and at incubations in human blood outside the body. Intact Long R3 became hard to detect earlier than some of its breakdown products in the rat samples. The authors also found oxidized forms in some tested products obtained from the unregulated market. Including those altered forms in an assay can help distinguish an intact compound from material that has changed. [1]
Detection depends on the sample type, the compound and the method's sensitivity. A detection window from rats does not establish a human half-life. The human serum experiments established features of the measurement method under laboratory conditions and did not measure a clinical effect. [1, 2]
Sources
Original works cited in this article. Links open the external record in a new tab.
- 2.Francis GL et al. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. Journal of Molecular Endocrinology (publication 1992-06). (opens in a new tab)
pubmed.ncbi.nlm.nih.gov↩ Back to text
